Your browser doesn't support javascript.
loading
Antigenic analysis of the influenza B virus hemagglutinin protein.
Zhang, Mengyi; Yang, Chaoying; Wu, Xi; Wang, Yifei; Wang, Lijie; Cui, Qianqian; Tong, Jincheng; An, Yimeng; Cai, Meina; Cheng, Shishi; Jiang, Qi; Wang, Yulin; Zhao, Chenyan; Wang, Youchun; Huang, Weijin.
Affiliation
  • Zhang M; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China; National Institutes for Food and Drug Control, Chinese Academy of Medical Science & Peking Union Medical College, Beij
  • Yang C; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China; National Vaccine & Serum Institute, Beijing, 101111, China.
  • Wu X; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China.
  • Wang Y; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China.
  • Wang L; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China.
  • Cui Q; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China.
  • Tong J; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China.
  • An Y; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China.
  • Cai M; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China.
  • Cheng S; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China.
  • Jiang Q; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China.
  • Wang Y; National Vaccine & Serum Institute, Beijing, 101111, China. Electronic address: wangyl_vigoo@163.com.
  • Zhao C; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China. Electronic address: zhaochenyan@nifdc.org.cn.
  • Wang Y; Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, 650031, China. Electronic address: wangyc@imbcams.com.cn.
  • Huang W; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China; National Institutes for Food and Drug Control, Chinese Academy of Medical Science & Peking Union Medical College, Beij
Virol Sin ; 2024 Sep 02.
Article in En | MEDLINE | ID: mdl-39233140
ABSTRACT
Influenza B viruses (IBVs) primarily infect humans and are a common cause of respiratory infections in humans. Here, to systematically analyze the antigenicity of the IBVs Hemagglutinin (HA) protein, 31 â€‹B/Victoria and 19 â€‹B/Yamagata representative circulating strains were selected from Global Initiative of Sharing All Influenza Data (GISAID), and pseudotyped viruses were constructed with the vesicular stomatitis virus system. Guinea pigs were immunized with three doses of vaccines (one dose of DNA vaccines following two doses of pseudotyped virus vaccines) of the seven IBV vaccine strains, and neutralizing antibodies against the pseudotyped viruses were tested. By comparing differences between various vaccine strains, we constructed several pseudotyped viruses that contained various mutations based on vaccine strain BV-21. The vaccine strains showed good neutralization levels against the epidemic virus strains of the same year, with neutralization titers ranging from 370 to 840, while the level of neutralization against viruses prevalent in previous years decreased 1-10-fold. Each of the high-frequency epidemic strains of B/Victoria and B/Yamagata not only induced high neutralizing titers, but also had broadly neutralizing effects against virus strains of different years, with neutralizing titers ranging from 1000 to 7200. R141G, D197 â€‹N, and R203K were identified as affecting the antigenicity of IBV. These mutation sites provide valuable references for the selection and design of a universal IBV vaccine strain in the future.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Virol Sin / Virol. sin. (Online) / Virologica sinica (Online) Journal subject: VIROLOGIA Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Virol Sin / Virol. sin. (Online) / Virologica sinica (Online) Journal subject: VIROLOGIA Year: 2024 Document type: Article Country of publication: